Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
About this item
Full title
Author / Creator
BURCHERT, A , WANG, Y , CAI, D , VON BUBNOFF, N , PASCHKA, P , MÜLLER-BRÜSSELBACH, S , OTTMANN, O. G , DUYSTER, J , HOCHHAUS, A and NEUBAUER, A
Publisher
London: Nature Publishing
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing
Subjects
More information
Scope and Contents
Contents
BCR/ABL-kinase mutations frequently mediate clinical resistance to the selective tyrosine kinase inhibitor Imatinib mesylate (IM, Gleevec). However, mechanisms that promote survival of BCR/ABL-positive cells before clinically overt IM resistance occurs have poorly been defined so far. Here, we demonstrate that IM-treatment activated the phosphatidy...
Alternative Titles
Full title
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2645717165
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2645717165
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/sj.leu.2403898
